



**Wellgistics
Health™**

**Redefining prescription
access across America**

Legal Disclaimer

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect current views of the Company with respect to, among other things, operations and financial performance. Forward-looking statements may be identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable” and similar terms and phrases in this presentation. Forward-looking statements contained in this presentation are based on the management’s current expectations and are subject to changes in circumstances and other risks and uncertainties. The Company cannot assure you that future developments affecting the Company will be those that the Company has anticipated. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond the control of the Company. Any forward-looking statement made by the Company in this presentation speaks only as of the date of this presentation. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions the Company may make. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.



Legal Disclaimer

Notice to Investors

The information set forth in this presentation has been prepared for informational purposes and does not constitute any offer to sell or the solicitation of an offer to buy any of the Company's securities, nor will there be any sales of the Company's securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction, or until a binding commitment to enter into a definitive agreement has been made. The Company expressly disclaims all liability relating to the use of this presentation. In addition, the information contained in this presentation is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. The delivery of this presentation and the information contained herein shall not create any liability or obligation whatsoever for the Company. No representations or warranties are made by the Company or any of the Company's affiliates as to the accuracy or completeness of any statements contained in this presentation or any additional materials. This presentation should not be considered as a recommendation by the Company or any of the Company's agents to acquire any securities or to enter into any transaction. This presentation shall neither be deemed an indication of the state of affairs of the Company's business nor constitute an indication that there has been no change in the Company's business affairs since the date hereof or since the dates as of which information is given in this presentation. In furnishing this presentation, the Company undertakes no obligation to provide the recipient with access to any additional evaluation materials or to update the information contained herein.

Industry and Market Data

In this presentation, the Company relies on and refers to certain information and statistics obtained from third-party sources which it believes to be reliable. However, the Company has not independently verified the accuracy or completeness of any such third-party information. The recipient is cautioned not to give undue weight to such industry and market data.

Trademarks, Trade Names and Service Marks

This presentation includes trademarks, trade names and service marks that the Company either owns or licenses, which are protected under applicable intellectual property laws. Solely for convenience, trademarks, trade names and service marks referred to in this presentation may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent under applicable law, rights or the right of the applicable licensor to these trademarks, trade names and service marks. This presentation may also contain trademarks, trade names and service marks of other parties, and the Company does not intend its use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of the Company by, these other parties.



Transforming the pharmaceutical fulfillment network without owning bricks and mortar.



Healthcare technology

Bringing pharmaceutical services to redefine prescription access across America



Cost Transparency:

Acquiring Peek Meds, one of the first Rx shopping marketplaces

Expected to close in Q2 2025



Full Stack Powering Patient Access:

Technology platform, wholesale distribution, and a network of 6,000+ pharmacies



Vertically-integrated:

Ecosystem seamlessly connects manufacturers, pharmacies, providers, employers and patients



Embedded AI:

Removes costs & helps uncover new opportunities



Removing barriers



Cutting costs




Streamlining the supply chain



Delivering faster, more affordable treatment



Centralized Intelligence with Best-in-Class Services



Pharmaceutical costs spiraling out of control
+15% per annum

99% of employers
believe drug prices are a significant
threat to healthcare affordability.

**The market
is broken.**





82% of adults

believe the cost of prescription drugs is

unreasonable

3 out of 10 adults skip treatments because

their drugs cost too much

Patients have had enough.



Multi-Billion Dollar Market for Drug Pricing Transparency



~\$1.1T

US Pharmaceutical market size,
2033P



\$16.9B+

Estimated AI-driven pharmacy
tools market size by 2034



27%

Estimated CAGR AI-driven
pharmacy tools, 2025-2034



~\$81B

Annual drug spend by
self-funded employers, covering
154M+ patient lives



PBMs charge manufacturers


Up to 60%
to access formulary



“Big Three” drug distributors
control

95%+
of the market


We're changing the paradigm: From the Manufacturer's door to the Patient's hands



**Employers see a significant reduction
in pharmaceutical costs**



Vertically Integrated, Tech-Driven Pharmacy Ecosystem



Distribution™

Wholesale Distributor
+ 3PL + Cold Chain

NABP Accredited in **all 50 States**

125+ Manufacturers
6,000+ Independent Pharmacies
(**30%+** Market Share & Growing)



Tech & Hub™

Digital Pharmacy and Hub
Platform

Patient App & Adherence Tools

Nationwide Network of
Pharmacies




Pharmacy™

Backend Pharmacy Services
Clinical Concierge

PA's / Therapeutic Interchange
Co-Pay / Discount Cards

35 State Licenses and Expanding
Direct-to-Patient Mail

Monetization across the entire Value Chain



Proprietary EinsteinAI allows us to uncover opportunities using pharmacy KPIs & point-of-sale data.


Acquisition of Peek Meds:

One of the *first* Rx shopping marketplaces

Other popular Rx savings programs *only reveal their own pricing...*



We harness the power of **savings solutions** available to patients and employers.



Peek Meds Marketplace provides patients **personalized, comparison pricing in one place:**

Highlights pharma **copay offset programs** to promote added savings

Includes patient's **insurance price**

Integrates **multiple** cards & discount programs to find the **lowest** cash price

Compares prices at **nearby** pharmacies

Designed to protect employers from fiduciary lawsuits

Vertical integration means we can do what others can't.

Unlike other popular Rx savings programs that **only** reveal *their own pricing*,
and **require a lengthy time to implement...**

We combine technology, supply chain, and market access expertise to harness the power of savings solutions from manufacturer direct, employer, and copay card marketplaces. Available to patients and employers – delivered immediately, without the wait or middleman markup.



Peek Meds Acquisition:



Unlocking **B2B2C** distribution



18-23%+

Top-line
cost savings



2M+


Claims evaluated in
last 6 months



95%

NDCs match

Industry-leading partners include:



Drives **patient engagement** & reduces abandonment




Expands market endpoints **with B2B2C distribution**




Allows manufacturers to fulfill **direct-to-consumer** via Wellgistics

Wellgistics AI: Leveraging AI to make our process faster, simpler and easier



Launched
2024



Direct AI integration with
our existing tech stack

Improve patient access with key components:



AI Consent



AI Enrollment



AI Benefit
Verification



AI Prior
Authorization



AI Copay
Assistance



AI Sales



AI Customer
Service

Unified Tech Platform



**OUR FULLY-INTEGRATED ECOSYSTEM
CONNECTS EVERY TOUCHPOINT,
ENABLING:**



Seamless
Pharmacy Operations



Direct Manufacturer
Fulfillment



Patient Savings
Transparency



Better Patient Access




Wellgistics' sustainable moat through vertical integration




Distribution™

- Manufacturer **Direct Relationships**
- **3PL & Cold Chain** Capabilities
- **Speed Advantage** over Incumbents



Tech & Hub™


- Hub Services
Central Ecosystem
- Integrated **AI**
- End-to-End
Pharmacy Software Integrations



Pharmacy™

- **35 State Licenses & Expanding**
- **6,000+** Pharmacy Network Nationwide
- (Peek Meds) **Direct Path** to Patients

Vertically-Integrated Prescription Integration Timeline



We plan to launch **differentiated products** that deliver even more value, access & transparency to patients.

Expert leaders in growth execution



Brian Norton
CEO

W Financial leader with 23+ years of progressive experience in cross border M&A, VC &, PE fund raising



Tony Madsen
COO

W Managing Partner of Healthtech investor Nomad Capital, with focus on first-mile of drug distribution (wholesale, distribution network & supply chain)



Mark DiSiena, CPA, Attorney, MBA
CFO

W Advisor and CFO for publicly-listed companies with prior roles at Oracle, LVMH and PWC; CA CPA and retired attorney



Srini Kalla
CIO

W Former senior IT executive at OptumRx and Elevance Health, with a focus on Pharmacy and PBM healthcare technology, leading major technology initiatives and M&A activities



Michael Navin
CCO

W Founded Peek Technologies & previously exited EMG to Ogilvy Health

W **Effective upon the closing of Peek Acquisition**



Shelley Bailey
CSO

W Former co-owner and CEO of Central Drugs Specialty Pharmacy, founder of Famlee Health, and Chair of Oregon Prescription Drug Affordability Board



Jason Lang, PharmD
President of Distribution

W Serial entrepreneur with multiple 7-figure exits, founded multiple pharmacies; prior role in Pharmacy Management with Walgreens



Dr. Shafaat Pirani, PharmD, BCGP
Chief Clinical Officer

W Previously Chief Clinical & Regulatory Compliance Officer, Bonum and TRxADE Health; formerly EVP DelivMeds and Director Ops for an independent mail-order facility

Landmark support for PBM reform at Federal & State level



Current administration has clearly expressed its support for:

- Wellgistics Health Lowering the cost of prescription drugs
- Wellgistics Health Patient costs transparency
- Wellgistics Health Health equity with patient access
- Wellgistics Health Fair, transparent & open markets
- Wellgistics Health Open competition



Wellgistics Health's promise of faster, cheaper, more transparent prescription care is well-aligned with the administration's policy goals

Wellgistics Health is seeking to:



Expand our **vertically integrated** pharmacy and distribution **network**



Accelerate **direct-to-manufacturer programs** to deliver lower-cost, higher-access prescriptions



Grow employer carve-out solutions to **increase transparency and affordability** in prescription benefits



Deploy AI-powered technologies like **Wellgistics AI** and **Peek Meds Marketplace** at national scale



Drive strategic partnerships with manufacturers, employer groups, and healthcare organizations

Imagine a world where...



Employers lower prescription drug costs by **up to 60%**.



Patients get **instant, real-time access to the best price** at their chosen pharmacy.




Manufacturers **bypass rebate middlemen** and reach patients directly — faster and more profitably.



Technology powers a **seamless, transparent prescription experience** across America.

Wellgistics Health is leading the transformation toward a smarter, **more affordable, patient-first prescription ecosystem.**



Prescription Price Transparency.

[wellgisticshealth.com](https://www.wellgisticshealth.com)



Contact

Brian Norton

bnorton@wellgisticshealth.com

(435) 669-6312



Wellgistics
HealthTM

Annex

Board of Directors



Suren Ajjarapu

Chairman

- W Founder, Chairman, and CEO of TRxADE Health, Inc. (n/k/a Scienture Holdings, Inc.)
- W Entrepreneur with leadership in Pharmaceuticals, Biofuels and Information Technology sectors
- W **Education:** MS in Environmental Engineering and an MBA specializing in International Finance and Management, and the Venture Capital and Private Equity program at Harvard University



Prashant Patel

Vice Chairman

- W Co-Founder, Director, President and COO of TRxADE Health, Inc. (n/k/a Scienture Holdings, Inc.)
- W Pioneered innovative technology for secondary distribution, reverse distribution, and logistics
- W **Education:** Bachelor of Pharmacy from the University of Nottingham/UK and an MSC in Transport, Trade & Finance from Cass Business School, City University, UK



Don Anderson

Board Member

- W Previously the President & CEO of Independent Pharmacy Cooperative (IPC) from 2009-2022, Board Member of the Federation of Pharmacy Networks and Choice Rx Solutions
- W Mergers and acquisitions, business operations, sales, and marketing
- W **Education:** Bachelor of Science in Business, Master of Business Administration from Chadwick University



Michael Peterson

Board Member

- W Former investment banker with 15 years at Goldman Sachs & Co. and Merrill Lynch
- W Founder & CEO, Lafayette Energy; Former interim CEO of Trio Energy (NYSE: TPET), and founded PEDEVCO (NYSE: PED)
- W **Education:** MBA, Finance and BS, Statistics & Computer Science from Brigham Young University



Rebecca Shanahan

Board Member

- W Board of Directors of the National Association of Specialty Pharmacies, Proxsys, Hatch and TruDataRx
- W Built and led specialty and compounding pharmacies: Priority Healthcare, Aetna Specialty Pharmacy, Oncology Therapeutics Network, Oncology Plus, Shoppers Drug Mart and Avella Specialty Pharmacy
- W **Education:** Indiana University School of Law

Revenue & Margin



SOURCES OF REVENUE

Wholesales **Distribution**

Prescription **Fulfillment**

Pharmaceutical **Manufacturer Services**

Prior Authorizations

Therapeutic Interchange

Recurring **revenue:**

SaaS Transactional Services

Rx Transfer
Clicks

Use of
technology

Provider, PMS,
Surescripts

Subscription Fees

Network Pharmacies

Patients


Multiple Rx refills

Monetizing data

Tech & Specialty Lite focus drives higher margins



FUTURE REVENUE DISTRIBUTION



- WGX Distribution
- WGX Pharmacy
- WGX Tech & Hub
- Patient & 3rd Party

Diverse revenue streams reduce risk

Estimate/Projection



MARGIN PROFILE



As the company scales...

Revenue shifts from low margin distribution to higher margin services



Leaders in executing growth strategies



Brian Norton

CEO

- Financial leader with 23+ years of progressive experience in cross border M&A, VC & PE fund raising
- Extensive track record of success and expertise in healthcare, technology, and pharmaceutical supply chain innovation
- Has led high-performing teams to accelerate market growth and revenue recognition



Michael Navin

CCO

- Big & small pharma experiences
- Founder of Peek Technologies transparency tool for prescription drugs
- Started EMG – launched 150 drugs, getting payors & MFRS together, sold to Ogilvy Health
- Strong background in branding, market access, trade & distribution



Shelley Bailey

CSO

- Chair of Oregon Prescription Drug Affordability Board (PDAB) since 2022
- Formerly co-owner and CEO of Central Drugs Specialty Pharmacy, exited to ProCare (CVS) in 2018
- Founded Famlee Health, a digital health company focused on affordable fertility treatment
- Experience with supply chain from pharma, payor, to patient



Tony Madsen

COO

- Deep experience in past roles with CEO Brian Norton
- Focus on first-mile of drug distribution (wholesale, distribution network & supply chain)
- Managing Partner of Nomad Capital, an investor in healthcare, tech and regulated industries
- Prior role as Director of Cybersecurity at Cingo Solutions, a SOC2-certified managed detection and response cybersecurity provider

Operational Highlights



Q1 2025 OPERATIONAL HIGHLIGHTS INCLUDE:

22

New Pharmaceutical Manufacturers Onboarded

57

New Prescription Drug Products Integrated into the Portfolio

354

New Independent Pharmacies Added to Nationwide Network

Target Margin by business line

Q1 2025 Operational Highlights	Q1 2025
New Pharmacy Manufacturers Onboarded	22
New Prescription Drug Products Integrated into Portfolio	57
New Independent Pharmacies Added to Nationwide Network	354
<i>Distribution</i>	10.7M
<i>SG&A of 31.2M less 27.8 in no cash stock comp, Net</i>	3.4M
<i>EPS less non-stock comp</i>	-0.3